Histone Deacetylase Inhibitors Market Report 2025

This Histone Deacetylase Inhibitors market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.2 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to regulatory support and fast-track approvals, the growing prevalence of cancer, increased funding for cancer research, the expansion of therapeutic applications, and increased expenditure on healthcare infrastructure.

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.

The rising incidence of cancer is expected to drive the growth of the histone deacetylase inhibitors market. This increase in cancer cases is largely due to factors such as aging populations, higher exposure to risk factors such as tobacco, diet, and environmental pollutants, and advancements in diagnostic techniques that lead to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, causing cell cycle arrest and apoptosis in cancer cells. For example, in February 2024, the World Health Organization predicted that approximately 35 million new cancer cases would occur in 2050, a 77% increase from the estimated 20 million cases in 2022. Thus, the growing incidence of cancer is boosting the histone deacetylase inhibitors market.

Major companies in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to provide more treatment options and enhance patient convenience and compliance. An oral HDAC inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and can be used to treat various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italian pharmaceutical company, received FDA approval for Duvyzat (givinostat), an oral HDAC inhibitor, for treating Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat mitigates muscle damage by reducing inflammation and fibrosis while promoting muscle fiber regeneration, slowing the progression of muscle deterioration associated with DMD. This approval was based on the pivotal phase 3 EPIDYS trial, which showed that patients on Duvyzat had a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.

In January 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly strengthen and diversify Bristol Myers' oncology portfolio, which includes the lung cancer medicine KRAZATI (adagrasib) and a leading KRAS and KRAS-enabling program with two Phase 1 candidates. The goal is to accelerate the development and delivery of innovative cancer treatments and enhance Bristol Myers' long-term growth in oncology. Mirati Therapeutics Inc. is a US-based targeted oncology company specializing in developing cancer therapeutics and histone deacetylase inhibitors.

Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC.

North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the histone deacetylase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Histone deacetylase inhibitors are compounds that disrupt the function of histone deacetylases, which are enzymes responsible for removing acetyl groups from histone proteins. This disruption can lead to increased acetylation of histones, resulting in a more relaxed chromatin structure and changes in gene expression.

Histone deacetylase inhibitors are mainly classified into Class I, Class II, Class III, and other types. Histone deacetylases are a group of enzymes that remove acetyl groups from histone proteins, causing chromatin condensation and transcriptional repression. These inhibitors can be administered orally, via injection, and are available through hospital pharmacies, online pharmacies, retail pharmacies, among others. They are useful in various fields such as oncology and neurology, with end users including hospitals, home care settings, specialty clinics, and other facilities.

The histone deacetylase inhibitors market research report is one of a series of new reports that provides histone deacetylase inhibitors with a histone deacetylase inhibitors market share, detailed histone deacetylase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. This histone deacetylase inhibitors market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.